[go: up one dir, main page]

TR200001558T2 - Yeni bileşikler. - Google Patents

Yeni bileşikler.

Info

Publication number
TR200001558T2
TR200001558T2 TR2000/01558T TR200001558T TR200001558T2 TR 200001558 T2 TR200001558 T2 TR 200001558T2 TR 2000/01558 T TR2000/01558 T TR 2000/01558T TR 200001558 T TR200001558 T TR 200001558T TR 200001558 T2 TR200001558 T2 TR 200001558T2
Authority
TR
Turkey
Prior art keywords
group
formula
pharmaceutical compositions
new compounds
preparing
Prior art date
Application number
TR2000/01558T
Other languages
English (en)
Inventor
Baxter Andrew
Brough Stephen
Mcinally Thomas
Mortimore Michael
Cladingboel David
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of TR200001558T2 publication Critical patent/TR200001558T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/26—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Bulus formül (I) ile gösterilen adamamtan türevlerine, bunlari hazirlama yöntemine, bunlari ihtiva eden farmasötik bilesimlere, farmasötik bilesimleri hazirlama yöntemine ve bunlarin tedavide kullanimlarina iliskin bir bulustur. Söz konusu formül (I) dahilinde, A bir CH2 grubunu veya bir oksijen atomunu temsil etmekte; B bir hidrojen veya halojen atomunu temsil etmekte; D bir CH2,OCH2,NHCH2 VEYA CH2CH2 grubunu temsil etmekte;R ise bir fenil, benzotiazolil, indolil, indazolil,purinil,piridil,pirimidinil veya tiofenil grubunu temsil etmektedir ve bunlarin her biri istege bagli olarak bir veya daha fazla ikame ile ikame edilebilmektedir.
TR2000/01558T 1997-12-05 1998-12-01 Yeni bileşikler. TR200001558T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704545A SE9704545D0 (sv) 1997-12-05 1997-12-05 Novel compounds

Publications (1)

Publication Number Publication Date
TR200001558T2 true TR200001558T2 (tr) 2000-10-23

Family

ID=20409282

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01558T TR200001558T2 (tr) 1997-12-05 1998-12-01 Yeni bileşikler.

Country Status (24)

Country Link
US (1) US6242470B1 (tr)
EP (1) EP1036058B1 (tr)
JP (1) JP2001525391A (tr)
KR (1) KR20010032708A (tr)
CN (1) CN1280560A (tr)
AT (1) ATE234274T1 (tr)
AU (1) AU746716B2 (tr)
BR (1) BR9813368A (tr)
CA (1) CA2312889A1 (tr)
DE (1) DE69812159T2 (tr)
DK (1) DK1036058T3 (tr)
EE (1) EE200000320A (tr)
ES (1) ES2195433T3 (tr)
HU (1) HUP0100431A3 (tr)
IL (1) IL136503A0 (tr)
NO (1) NO20002785L (tr)
NZ (1) NZ504375A (tr)
PL (1) PL340890A1 (tr)
PT (1) PT1036058E (tr)
RU (1) RU2197477C2 (tr)
SE (1) SE9704545D0 (tr)
SK (1) SK8412000A3 (tr)
TR (1) TR200001558T2 (tr)
WO (1) WO1999029660A1 (tr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061569A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
RU2272025C2 (ru) * 1999-12-17 2006-03-20 Астразенека Аб Производные адамантана, способы их получения, фармацевтическая композиция на их основе и способ ее получения, способы лечения ревматоидного артрита и хронического обструктивного заболевания легких
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
EP1741722A3 (en) * 2000-10-21 2007-03-14 AstraZeneca AB Polymorphisms in the human P2X7 gene
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
US6995285B2 (en) * 2000-12-07 2006-02-07 Cv Therapeutics, Inc. ABCA-1 elevating compounds
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CA2501547A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ES2396565T3 (es) * 2003-05-12 2013-02-22 Pah Usa 15 Llc Inhibidores benzamida del receptor P2X7
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
KR100643511B1 (ko) 2004-07-14 2006-11-10 (주)아모레퍼시픽 히드록삼산 유도체 및 이의 제조방법
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
EA200901463A1 (ru) 2004-02-20 2010-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
CA2571124A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
BRPI0512651A (pt) * 2004-06-29 2008-03-25 Pfizer Prod Inc método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
EP1632491A1 (en) 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
SI1827437T1 (sl) * 2004-12-15 2012-02-29 Sigma Tau Ind Farmaceuti Kombinacije terapevtskih sredstev za zdravljenje raka
ZA200706804B (en) * 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
DK1937643T3 (en) 2006-03-16 2016-10-10 Second Genome Inc Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
WO2007109201A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
ES2569677T3 (es) 2006-03-16 2016-05-12 Second Genome, Inc. Compuestos bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
HUE026011T2 (en) * 2006-03-22 2016-05-30 Hoffmann La Roche Pyrazoles as 11-beta-HSD-1
WO2007113671A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
BRPI0719280A2 (pt) 2006-11-27 2014-03-11 Lundbeck & Co As H Composto, composição farmacêutica, métodos para modular a atividade de um receptor de p2x7 in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, para determinar a presença ou ausência de receptor de p2x7 em uma amostra, preparação farmacêutica acondicionada, método para tratar ou prevenir cirrose em um paciente, e, uso de um composto.
EP2099489B1 (en) * 2006-12-11 2014-05-21 Genentech, Inc. Compositions and methods for treating a neoplasm
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
KR20090122396A (ko) 2007-03-22 2009-11-27 아스트라제네카 아베 염증성 질환 치료용 퀴놀린 유도체
UA99610C2 (en) 2007-04-10 2012-09-10 Х. Луннбэк А/С Heteroaryl amide analogues as p2x7 antagonists
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
EA017250B1 (ru) * 2007-07-19 2012-11-30 Х. Лундбекк А/С 5-членные гетероциклические амиды и их применение для модуляции рецептора p2x
US10308514B2 (en) 2007-09-07 2019-06-04 Cbn Nano Technologies Inc. Systems and methods for the manufacture of atomically-precise products
CL2008002782A1 (es) * 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
JP5423679B2 (ja) 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
KR100899335B1 (ko) * 2007-11-27 2009-05-26 (주)아모레퍼시픽 엘라스테아제 저해 효과를 보이는 아다만탄 유도체 화합물및 그 제조방법
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
EP2105164B1 (en) * 2008-03-25 2011-01-12 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
PT2243772E (pt) 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e sua utilização
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
EP2569301A1 (en) 2010-05-12 2013-03-20 Abbvie Inc. Indazole inhibitors of kinase
AU2011252351A1 (en) 2010-05-14 2012-10-11 Affectis Pharmaceuticals Ag Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101957843B1 (ko) * 2011-10-06 2019-03-14 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
CN103319493B (zh) * 2012-03-19 2016-02-10 艾琪康医药科技（上海）有限公司 一种合成1-羟甲基-3-氢-2-氧杂金刚烷及其衍生物的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US10197597B2 (en) 2013-02-28 2019-02-05 Cbn Nano Technologies Inc. Build sequences for mechanosynthesis
US9676677B2 (en) 2013-02-28 2017-06-13 Robert A. Freitas, JR. Build sequences for mechanosynthesis
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
KR102529578B1 (ko) 2014-08-29 2023-05-09 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
WO2016032182A1 (ko) * 2014-08-29 2016-03-03 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
RU2608631C1 (ru) * 2015-10-27 2017-01-23 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) Адамантансодержащие индолы и их гидрохлориды, обладающие свойством стабилизации микротрубочек, способы их получения, фармакологическое средство на их основе и способ лечения и предупреждения заболеваний, связанных с нарушениями системы микротрубочек
RU2608737C1 (ru) * 2015-10-27 2017-01-23 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) Применение адамантансодержащих индолов и их гидрохлоридов в качестве цитопротекторов и для лечения и предупреждения заболеваний, связанных с увеличением цитозольной концентрации кальция, и фармакологическое средство на их основе
RU2621348C1 (ru) * 2016-03-25 2017-06-02 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) Применение адамантансодержащих индолов и их гидрохлоридов в качестве ингибиторов холинэстераз и блокаторов nmda-рецепторов
US10067160B2 (en) 2016-11-16 2018-09-04 CBN Nano Technologies, Inc. Sequential tip systems and methods for positionally controlled chemistry
WO2018093728A1 (en) 2016-11-16 2018-05-24 Nanofactory Corporation Systems and methods for mechanosynthesis
CN109956973B (zh) * 2017-12-25 2020-11-03 上海启甄环境科技有限公司 一种放射性同位素碳-14标记毒氟磷的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3789072A (en) 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
CA2015473C (en) * 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
ATE197146T1 (de) 1993-08-10 2000-11-15 Black James Foundation Gastrin-und cck-rezeptorligande
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
RU2068840C1 (ru) * 1994-07-18 1996-11-10 Волгоградский государственный технический университет 1-(4'-аминофенил)-3-аминоэтиладамантан - мономер для синтеза полиимидов и сополиимидов с повышенной гидролитической устойчивостью

Also Published As

Publication number Publication date
NZ504375A (en) 2003-08-29
BR9813368A (pt) 2000-10-03
WO1999029660A1 (en) 1999-06-17
SE9704545D0 (sv) 1997-12-05
DE69812159D1 (de) 2003-04-17
NO20002785D0 (no) 2000-05-31
NO20002785L (no) 2000-08-01
AU1791499A (en) 1999-06-28
CN1280560A (zh) 2001-01-17
IL136503A0 (en) 2001-06-14
ES2195433T3 (es) 2003-12-01
HUP0100431A3 (en) 2002-12-28
US6242470B1 (en) 2001-06-05
DK1036058T3 (da) 2003-06-30
PL340890A1 (en) 2001-03-12
EE200000320A (et) 2001-08-15
CA2312889A1 (en) 1999-06-17
HK1028594A1 (en) 2001-02-23
HUP0100431A2 (hu) 2001-07-30
EP1036058B1 (en) 2003-03-12
ATE234274T1 (de) 2003-03-15
RU2197477C2 (ru) 2003-01-27
KR20010032708A (ko) 2001-04-25
DE69812159T2 (de) 2003-12-18
AU746716B2 (en) 2002-05-02
SK8412000A3 (en) 2000-11-07
PT1036058E (pt) 2003-07-31
EP1036058A1 (en) 2000-09-20
JP2001525391A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
TR200001558T2 (tr) Yeni bileşikler.
DE3673094D1 (de) (meth)-acrylsaeure-derivate von tricyclodecanen und ihre verwendung.
NL1001124A1 (nl) Met alkoxyfenyl gesubstitueerde bisacylfosfineoxiden.
ATE256699T1 (de) Entzündungshemmende tyrosin-derivate
HUP0003068A2 (hu) Sejtburjánzást gátló kalkonszármazékok, ezeket tartalmazó gyógyászati készítmények, alkalmazásuk gyógyszerként, valamint gyógyászati készítmények előállítására
ATE9336T1 (de) 3,1-benzoxazin-2-one, ihre herstellung und verwendung.
NO971142L (no) Bis-(2-halogenetyl)aminofenylsubstituerte distamycinderivater som antitumor- og antivirale midler
DE3572809D1 (de) Microbicidal 1-fluoro-1-azolyl-2,2-diarylethane derivatives
DE59009359D1 (de) Phenylalkylamine und diese enthaltende Fungizide.
ATE28639T1 (de) Derivate von 4-(3-alkynyloxy-2-hydroxy-propyl)piperazin-1-yl-n-phenylacetamid, ihre herstellung und ihre therapeutische verwendung.
DK160271C (da) Analogifremgangsmaade til fremstilling af 5-halogenvinyl-uracil-derivater
ES418113A1 (es) Un procedimiento para la preparacion de nuevas piperacino- pirimidinas.
SE8000367L (sv) Fenoxi- och tiofenoxintriler och anvendning derav
GB1504016A (en) Fungicidal agents
TR199801683A2 (tr) Yeni üre türevleri.
ATE5144T1 (de) Thiazolderivate, ihre herstellung und ihre therapeutische anwendung.
DK272482A (da) Tricykliske forbindelser
DK513281A (da) Fremgangsaade til fremstilling af 3-thiovinylcephalosproner
ES480216A1 (es) Procedimiento para la preparacion de nuevos compuestos de estilbeno.
ATE121937T1 (de) Verwendung von 2h-1,2,4-benzothiadiazin-3(4h)- thion-1,1-dioxiden als antivirale arzneimittel.
DK231787D0 (da) 3-amino-dihydropyridiner, fremgangsmaade til deres fremstilling og deres anvendelse i laegemidler
ATE19629T1 (de) N-substituierte derivate des tetrahydroisophthalimids.
ATE164069T1 (de) Verwendung von 5-thia-1,4-diazabicyclo (4.2.0> octane-3,8-dioxo verbindungen in der antitumor- therapie
ES8202824A1 (es) Procedimiento para la preparacion de nuevos derivados de pi-razolilpirimidina
ES412549A1 (es) Procedimiento para la preparacion de derivados de 1,4-dia- zacicloalcano.